Advances in Allergen Immunotherapy and Safety
Vaccines · 23.02.2025 · 13 (3) · 221
DOI: 10.3390/vaccines13030221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 23.02.2025. Verfasst von Samia T Al-Shouli. Beteiligte Einrichtung: Immunology Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Allergen immunotherapy (AIT) modifies immune responses to treat allergies. AIT treatment is a 3-month to 3-year long-term strategy, and its potential candidates are allergic rhinitis and asthma, food allergy, and insect venom allergy. AIT can be administered through specific routes recognized for allergy treatment strategies. A considerable body of knowledge about AIT is available, and the Food and Drug Administration (FDA) has approved the first peanut oral immunotherapy (OIT). The AIT effective type for other allergens and the route of administration are a real challenge. This paper reviews published literature on AIT mechanisms, administration routes, and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunology Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.
ORCID-Profile: Samia T Al-Shouli
Zitieren
APA
Al-Shouli, S. T. (2025). Advances in Allergen Immunotherapy and Safety. Vaccines, 13(3), 221. https://doi.org/10.3390/vaccines13030221
Vancouver
Al-Shouli ST. Advances in Allergen Immunotherapy and Safety. Vaccines. 2025;13(3):221. doi:10.3390/vaccines13030221
BibTeX
@article{AlShouli2025,
author = {Al-Shouli, Samia T},
title = {Advances in Allergen Immunotherapy and Safety},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {3},
pages = {221},
doi = {10.3390/vaccines13030221}
}
EUVIMED